Publications by authors named "Ziriab Lisri"
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can significantly improve cancer treatment outcomes but are linked to serious side effects, including kidney issues like acute tubulointerstitial nephritis and glomerulonephritis.
- A reported case of severe IgA nephropathy (IgAN) developed within 5 months of starting ICIs, highlighting the need for awareness and monitoring of kidney health in patients receiving these treatments.
- While IgAN is less common than acute tubulointerstitial nephritis, it may often go undetected; thus, doctors should routinely check for symptoms like hematuria before administering ICIs.
